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Background
Graves’ disease is the most common cause of thyrotoxico-
sis in children. Prepubertal children are the most difficult
to treat with remission attained in less than 15% [1,2].
Objective: To characterise clinical features and review
treatment outcome among children with very early
onset Graves’.
Methodology
Retrospective medical record review of patients diag-
nosed with Graves’ disease at age less than 8 years, who
received treatment in our department in the last
14 years.
Results
Sixteen patients (2 males) were identified with median
age at diagnosis of 4.96 years (range 2.5-7.83). Present-
ing symptoms were hyperactivity, weight loss, poor sleep
and diarrhoea. They had predominant non-Anglo-Saxon
ethnicity. Significant co-morbidities were- Down syn-
drome [1], juvenile idiopathic arthritis [1], situs inversus
with extrahepatic biliary atresia ie EHBA [1].Two had
family history of Graves’ disease. All had goitre,
increased serum Free T4 (median 53.65 pmol/l, range
35-94), increased serum Free T3 (median 33.5 pmol/l,
range 19.3-46) and suppressed TSH levels. All were
positive for TSII (thyroid stimulating immunoglobulin)
or TRAb (thyrotropin receptor antibody). Anti thyroid
peroxidise was positive in 83.3% (10/12) and anti thyro-
globulin in 80% (8/10). Anti-thyroid drugs (ATD) alone
were used in 9 patients, 4 received one dose each of
radio-active iodine ablation (10-15 mCi) and 3 under-
went thyroidectomy. Our cohort tolerated the ATD’s
well- Only 1 had significant liver enzyme elevation
(underlying EHBA) after Neomercazole, minor side-
effects were: skin rash (3) and arthralgia [1]. Data from
patients with more than 30 months follow-up was used
to assess outcome. Twelve children with median follow
up of 66 months (range: 34-161) and median age of
10.13 years (range: 7.17-16) at last clinic visit qualified.
Remission was attained in 58.3% (7/12) - 3 were post
thyroidectomy, 1 post radio-active iodine ablation and 3
received only ATD’s. Growth monitoring showed decline
in median weight sds from 0.41 at diagnosis to 0.29 at
follow up and height sds from 1.35 to 0.69. Of the sixteen
patients 2 girls were followed through their puberty till
16 years of age and both are in remission (1 underwent
thyroidectomy and other received Neomercazole).
Conclusion
Our cohort had 16 patients diagnosed with Graves’ at a
median age of 4.96 years. Overall remission for those
with more than 30 months follow-up is 58.3% (7/12), at
a median age of 10.13 years. Thyroidectomy had a
remission rate of 100%, ATD’s alone of 33.3% and one
dose of radioactive iodine ablation of 25%.
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